Joshi J Alumkal, MD

Joshi Alumkal
Wicha Family Professor of Oncology and Professor of Internal Medicine, Medical School
Email:
[email protected]
Phone:
Available to mentor
Joshi J Alumkal, MD
Joshi Alumkal
Professor
  • About
  • Center Memberships
  • Recent Publications
  • Manage Your Profile

  • About

    Dr. Alumkal graduated summa cum laude from the University of Texas with a B.A. in Biology. Then, he received his medical degree from Baylor College of Medicine. He completed an internship, residency, and chief residency at UT Southwestern Medical Center. After completing a clinical fellowship in medical oncology at Johns Hopkins University, Dr. Alumkal completed a post-doctoral fellowship focused on cancer epigenetics in the Jim Herman Laboratory at Johns Hopkins. Dr. Alumkal joined the Knight Cancer Institute Prostate Cancer Research Program at Oregon Health and Science University (OHSU) in 2007 and became the co-Leader of the Program in 2013. In 2014, Dr. Alumkal was honored with the Richard T. Jones New Investigator Award for exceptional promise early in a career in biomedical research in Oregon. He was also named the inaugural holder of the Wayne D. Kuni and Joan E. Kuni Endowed Chair for Prostate Cancer Research at OHSU in 2017.

    In 2019, Dr. Alumkal re-located to the University of Michigan to lead the Genitourinary Medical Oncology Section in the Division of Hematology-
    Oncology and the Rogel Cancer Center, where he is a Professor of Internal Medicine. He was named a Rogel Cancer Center Rogel Scholar in 2019 and was elected to the American Society for Clinical Investigation that same year. Since 2020, he has been a Co-Leader of the Translational and Clinical Research Program in the Rogel Cancer Center. In 2021, Dr. Alumkal was named the inaugural Wicha Family Professor of Oncology at the University of Michigan.

    The Alumkal Laboratory’s main emphasis is to understand how tumors change and adapt in response to treatment. The most important goals of Dr. Alumkal’s studies are to identify therapies that effectively target and interdict lethal prostate cancer progression in the laboratory and to conduct innovative clinical trials designed to validate the molecular and clinical effectiveness of novel therapeutic agents.

    Center Memberships

    • Center Member
      MM-PKUHSC Joint Institute
    • Center Member
      Center for Cell Plasticity and Organ Design
    • Center Member
      Rogel Cancer Center
    • Center Member
      AI and Digital Health Innovation

    Recent Publications

    See All Publications
    • Journal Article
      Biomedical Data Manifest: A lightweight data documentation mapping to increase transparency for AI/ML
      Bottomly D, Suciu CG, Cordier B, Evans N, Poire A, Zheng C, Deininger M, Zang X, Witkiewicz A, Knudsen E, Boutros PC, Soragni A, Vlashi E, Lin C, Tran P, Chan KS, Alumkal J, Willey C, Liu T, Liu S, Goodrich DW, Druker B, Dong J, Hollingsworth M, Singh P, Koong A, Gan B, Roth J, Bivona T, Sandulache V, Myers J, Tyner JW, Hutson A, McWeeney SK. Scientific Data, 2026 Dec 1; 13 (1): DOI:10.1038/s41597-026-06670-0
      PMID: 41673000
    • Journal Article
      Convergent evolution of complex structural variants drives therapy resistance in metastatic prostate cancer
      Moreno-Rodriguez T, Zhang M, Lundberg A, Shrestha R, Sjöström M, Pasam A, Chan J, Devereux L, Foye A, Zhu X, Weinstein AS, Trigos AS, Wyatt AW, Alumkal JJ, Small EJ, Aggarwal R, Dehm SM, Bootsma ML, Zhao SG, Lupien M, Feng FY, Sandhu S, Quigley DA. Genome Biology, 2026 Dec 1; 27 (1): DOI:10.1186/s13059-026-04074-2
      PMID: 41987223
    • Journal Article
      ADT Combinations With Radiation for Prostate Cancer: A Systematic Review and Meta-analysis
      Takayesu JSK, Xie T, Aldous J, Nasser B, Alumkal JJ, Dess RT, Reichert ZR, Schipper MJ, Spratt D, Suresh K, Jackson WC. International Journal of Radiation Oncology Biology Physics, 2026 Nov 1; 126 (3): 662 - 671. DOI:10.1016/j.ijrobp.2026.06.3095
      PMID: 42472616
    • Journal Article
      Increasing cancer stemness drives prostate cancer progression, plasticity, therapy resistance and poor patient survival
      Liu X, Jamroze A, Cortes E, Ji Y, Zhao K, Zhao F, Ho J, Liu Y, Davicioni E, Wu S, Li WJ, Feng FY, Alumkal JJ, Spratt DE, Sweeney CJ, Yu H, Hu Q, Zou C, Zhang D, Lin K, Lu Y, Chatta G, Nastiuk KL, Goodrich DW, Rycaj K, Kirk JS, Puzanov I, Xia Z, Liu S, Wang J, Tang DG. Molecular Cancer, 2026 Oct 28; DOI:10.1186/s12943-026-02795-3
    • Journal Article
      EZH2 Inhibition and Myeloid Risk: A Feature of On-Target Biology
      Alumkal JJ, Ellis L. Clinical Cancer Research, 2026 Oct 15; 32 (20): 4525 - 4530. DOI:10.1158/1078-0432.CCR-26-2216
      PMID: 42599162
    • Journal Article
      Prospective Evaluation of Circulating Tumor DNA in Metastatic Hormone-Sensitive Prostate Cancer
      Nguyen CB, Tsung I, Lee JK, Pasquina LW, Kasputis A, Lovett JL, Graf RP, Redmond A, Cackowski FC, Heath EI, Smith DC, Alumkal JJ, Morgan TM, Reichert ZR. JCO Precision Oncology, 2026 Sep 1; 10 (9): DOI:10.1200/PO-25-01218
      PMID: 42715508
    • Preprint
      Increasing Cancer Stemness Drives Prostate Cancer Progression, Plasticity, Therapy Resistance and Poor Patient Survival.
      Liu X, Jamroze A, Cortes E, Ji Y, Zhao K, Zhao F, Ho J, Liu Y, Davicioni E, Wu S, Li WJ, Feng FY, Alumkal JJ, Spratt DE, Sweeney CJ, Yu H, Hu Q, Zou C, Zhang D, Lin K, Lu Y, Chatta G, Nastiuk KL, Goodrich DW, Rycaj K, Kirk JS, Puzanov I, Xia Z, Liu S, Wang J, Tang DG. 2026 Aug 15; DOI:10.1101/2025.04.27.650697
      PMID: 40458374
    • Journal Article
      Systematic analysis of hippo pathway signaling identifies TEAD1 as a transcriptional regulator of neuroendocrine prostate cancer
      Brown LG, Coleman IM, Chu TLH, Sayar E, Patel RA, Hanratty B, Adil M, Li D, Li Y, Nguyen HM, Sessions CJ, Sweeney EL, Alumkal JJ, da Costa RMG, Wang Y, Lin DW, True LD, Dumpit R, Corey E, Lee JK, Nelson PS, Xin L, Haffner MC, Morrissey C. Neoplasia United States, 2026 Aug 1; 78: DOI:10.1016/j.neo.2026.101321
      PMID: 42217442

    Featured News & Stories

    Microscope images of prostate cancer cells
    Health Lab

    New drug combination may help treat advanced prostate cancer

    University of Michigan researchers found that combining BET bromodomain and DNMT inhibitors may slow the growth of treatment-resistant prostate cancer by targeting transdifferentiated tumors.
    yellow pills spilling out of bottle
    Health Lab

    Study sheds light on why some prostate tumors are resistant to treatment

    A new study from University of Michigan Rogel Cancer Center researchers identifies a cellular signature that explains why about one-third of prostate cancers respond especially poorly to treatment. 
    cells purple some lighter cells in white
    Health Lab

    Researchers find early driver of prostate cancer aggressiveness

    University of Michigan Health Rogel Cancer Center scientists identified a gene that plays a key role in prostate cancer cells that have transitioned to a more aggressive, treatment-resistant form. The gene can be indirectly targeted with an existing class of drugs, suggesting a potential treatment strategy for patients with aggressive subtypes of prostate cancer.